Cardiovascular disease after Hodgkin's lymphoma: a role for screening
A partir de données portant sur des patients atteints d'un lymphome hodgkinien et inclus dans des essais cliniques européens entre 1964 et 2004, cette étude évalue les effets des anthracyclines, des vinca-alcaloïdes et de la radiothérapie sur les risques de maladie cardiovasculaire
In The Lancet Haematology, Maja Maraldo and colleagues have investigated cardiovascular disease burden using data from 6039 survivors of Hodgkin's lymphoma treated in nine European randomised trials between 1964 and 2004. Incidence of cardiovascular disease was reported during trial follow-up and was updated through a patient-reported questionnaire mailed in 2009–10. 703 first cardiovascular disease events were reported, the most frequent of which were ischaemic heart disease in 132 (19%) patients, arrhythmia in 110 (16%) patients, congestive heart failure in 85 (12%) patients, and valvular disease in 77 (11%) patients.